Please provide your email address to receive an email when new articles are posted on . Fewer than 2% of patients who received long-acting injectable antipsychotics were readmitted vs. 8.3% of those ...

SAN DIEGO -- Among patients with schizophrenia, most preferred long-acting injectable antipsychotics when given a choice, a researcher reported here. A post-hoc analysis of a randomized, controlled ...

Patients with schizophrenia appear to prefer long-acting injectable (LAI) antipsychotics compared with oral versions of these medications primarily because injectables are more convenient and give ...

COLORADO SPRINGS, Colorado — The long-term formulation of the antipsychotic paliperidone (Invega, Janssen Pharmaceuticals, Inc) significantly delays relapse in schizophrenia patients with no increase ...

A long-acting injectable antipsychotic delayed hospitalization for patients with schizophrenia in a manufacturer-sponsored cluster-randomized trial. Among 489 patients with schizophrenia and no prior ...

Please provide your email address to receive an email when new articles are posted on . Long-acting injectable antipsychotics have been shown to prevent symptom relapse while addressing patient ...

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia Long-acting injectable (LAI) antipsychotics may improve medication adherence and reduce relapse in patients with schizophrenia.

Long-acting injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment and outcomes in schizophrenia, but it has not been tested in a long-term randomized ...

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of ...

One of the most important goals in the treatment of people with schizophrenia is preventing relapses, which often lead to periods of hospitalization. Discontinuing Medication Can Cause Relapse in ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

A new study analyzing Medicaid databases from 2017 to 2021 has uncovered significant differences in how long-acting injectable (LAI) antipsychotic medications are prescribed to older adults across ...